“The fund liquidated its position in Utah Medical due to a class-action lawsuit and the loss of a major OEM customer. These setbacks created severe earnings uncertainty that overshadowed the company's strong cash flow history.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
